Aortic & peripheral vascular diseaseSecondary analysis
Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease
- Secondary analysis of the STRIDE randomised trial
- post hoc analysis
Authors' conclusion
In this post hoc analysis from STRIDE, semaglutide 1.0 mg exhibited consistent improvements in functional outcomes in people with early symptomatic PAD and T2D regardless of sex.
Study context
- Population
- Patients with early symptomatic peripheral artery disease (PAD) and T2DM
- Participants
- 792 patients
- Comparison
- Semaglutide 1.0 mg once weekly, efficacy by sex
- Femalesn = 195
- Malesn = 597
- Primary endpoint
- Ratio to baseline in maximum walking distance (MWD) on a constant load treadmill, by sex
- Follow-up
- Week 52
Primary result
As reported in the abstract
MWD ratio to baseline, by sex
Consistent improvement in maximum walking distance (MWD) across sexes, favouring semaglutide
P-interaction value = 0.65
Secondary outcomes
Baseline geometric mean MWD
Change in MWD, by sex · week 57
- Consistent trend for improved MWD favouring semaglutide in females and males
- P for interaction = 0.53
Change in pain-free walking distance, by sex · week 52
- Improvement consistent across sexes in favour of semaglutide
- P for interaction = 0.80
PAD-specific quality of life (VascuQoL-6), by sex · week 52
- Improvements with semaglutide in both sexes consistent with the overall trial
Original publication
Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease. J Am Coll Cardiol. Published 31 August 2025. doi:10.1016/j.jacc.2025.08.046
Summarised from the published abstract; every number is checked against it